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This abbreviated review outlines the physiologic changes associated with aging, and examines how these changes may affect the
pharmacokinetics and pharmacodynamics of anticancer therapies. We also provide an overview of studies that have been conducted
evaluating the pharmacology of anticancer therapies in older adults, and issue a call for further research.
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Cancer is a disease of older adults. Approximately 60% of cancer
diagnoses and 70% of cancer mortalities occur in individuals age
65 and older (Yancik and Ries, 2000). As the general population
ages and life expectancy increases, the number of older adults with
cancer is growing.
Several unique challenges arise in caring for older adults with
cancer. In particular, the physiologic changes associated with aging
can have an impact on the pharmacokinetics and pharmaco-
dynamics of cancer therapies. The effects of these age-related changes
on drug dosing and tolerance have been understudied, as clinical
trials that set the standards for oncology care and drug approval have
typically focused on a younger patient population (Hutchins et al,
1999; Talarico et al, 2004). Few studies have included patients who are
frail or who have a poor performance status (Table 1).
In this review, we provide an overview of the physiologic changes
that accompany aging that may have an impact on the pharmacol-
ogy of anticancer therapies. We also discuss recent studies
evaluating the pharmacology of anticancer therapies in older adults.
PHYSIOLOGIC CHANGES WITH AGING
Aging is a heterogenous process; however, some characteristic
changes in physiology and organ function can have an impact on
the pharmacology of anticancer therapy. For example, age-related
changes in the gastrointestinal tract may affect drug absorption.
These changes include a decrease in splanchnic blood flow,
gastrointestinal motility, secretion of digestive enzymes, and
mucosal atrophy (Yuen, 1990; Baker and Grochow, 1997). With
increasing age, hepatic mass decreases and there is a decrease in
the cytochrome p450 content in liver biopsies, although the impact
of these declines on hepatic function remains controversial
(Sotaniemi et al, 1997; Shah, 2004; Sawhney et al, 2005).
There is a decrease in renal mass and renal blood flow with
aging (Vestal, 1997). These age-related changes in renal function
could affect the pharmacology of anticancer drugs. A serum
creatinine is often used to approximate renal function in younger
adults; however, it is a poor indicator of renal function in older
adults because of a decrease in muscle mass with age (Fehrman-
Ekholm and Skeppholm, 2004). On average, the glomerular
filtration rate decreases by approximately 0.75mlmin
 1year
 1
after age 40; however, this decrease is not universal, and
approximately one-third of all patients will have no change in
creatinine clearance with age (Lindeman et al, 1985). Various
equations have been used to estimate glomerular filtration rate,
including the Cockcroft/Gault, Jeliffe, Wright, and MDRD (mod-
ification of diet in renal disease) formulas. The Cockcroft/Gault
and Jeliffe formulas have primarily been validated in younger
patients without renal disease (Burkhardt et al, 2002; Rimon et al,
2004). The Wright formula is more accurate than the Cockcroft/
Gault formula in patients with a glomerular filtration rate of 450
(Marx et al, 2004). The MDRD formula is more accurate than other
formulas in patients with chronic renal disease. This formula takes
into account age, sex, ethnicity, serum creatinine, blood urea
nitrogen, and albumin (Levey et al, 1999; Lichtman et al, 2007).
With increasing age, body composition changes, body fat
increases and total body water decreases. This in turn increases
the volume distribution of drugs that are lipid soluble and decreases
the volume distribution of drugs that are water soluble. Hypo-
albuminaemia and anaemia can lead to an increase in the volume
distribution of drugs that are bound to albumin or haemoglobin,
respectively. There is also an increase in bone marrow fat and a
decrease in bone marrow reserve with age. This decrease in bone
marrow reserve places older adults at increased risk for myelosup-
pressive complications from chemotherapy (Vestal, 1997).
Each of these physiologic changes that accompany aging could affect
the pharmacokinetics and pharmacodynamics of anticancer therapies.
CANCER THERAPY STUDIES IN OLDER ADULTS
Several recent studies have examined the effects of age-related
changes on the pharmacokinetics and pharmacodynamics of
common cancer therapies.
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Taxanes are primarily metabolised hepatically. The pharmacoki-
netics of paclitaxel 175mgm
 2 given every 3 weeks was evaluated
in 153 patients, ages 55–86. With higher age, there was an increase
in the area under the curve (AUC) of paclitaxel and a decrease in
drug clearance. This translated into an age-related increase in
grade 3 neutropenia and lower absolute neutrophil count (ANC)
nadir; however, there was no increase in the incidence of fever,
hospitalisation, or need for intravenous antibiotics (Lichtman et al,
2006). Common comorbid medical conditions in older adults may
impact tolerance to cancer therapy. For example, patients with
diabetic neuropathy may be at increased risk for neurotoxicity to
taxanes (Rowinsky et al, 1993).
The pharmacokinetics of docetaxel at 75mgm
 2 every 3 weeks
was evaluated in 40 patients. There was no significant difference in
the pharmacokinetics of docetaxel in patients older or younger
than age 65; however, older adults were more likely to experience
febrile neutropenia and grade 4 neutropenia (ten Tije et al, 2005).
A population pharmacokinetics study of 640 patients who received
docetaxel demonstrated a small overall impact related to age, but a
large impact of abnormal liver function tests on docetaxel
clearance. On the basis of these data, the authors recommended
that dose adjustments be made in patients with abnormal liver
function tests; however, no specific dose adjustment was
recommended based on age (Bruno et al, 2001).
Studies evaluating the pharmacokinetics and pharma-
codynamics of weekly paclitaxel and docetaxel have yielded
conflicting results (Fidias et al, 2001; Smorenburg et al, 2003;
Minami et al, 2004; Slaviero et al, 2004; Hurria et al, 2006). The
majority of these studies revealed no significant age-related
differences in the pharmacokinetics of weekly taxanes; however,
one small study (N¼8) noted a 50% decrease in the clearance of
unbound paclitaxel with increasing age (Smorenburg et al, 2003).
A newer formulation of taxane, nab-paclitaxel, is albumin-
bound and Cremophor-free, eliminating the need for steroid
premedication. This makes it an attractive option for older adults,
particularly those with comorbidities such as diabetes, which can
be exacerbated with steroid premedication (Nyman et al, 2005). To
date, no studies have been conducted into age-related changes in
the pharmacokinetics of nab-paclitaxel, and this offers an
important area for future research.
Alkylating agents
Cisplatin and carboplatin Both cisplatin and carboplatin rely on
renal clearance and have a similar mechanism of action. The
clearance of the drugs is triphasic in nature, consisting of a
distribution half-life (13min for cisplatin; 22min for carboplatin),
elimination half-life (43min for cisplatin; 116min for carboplatin),
and terminal half-life (5.4 days for cisplatin; 5.8 days for
carboplatin). Potential cisplatin toxicities that require early
evaluation, dose modification, and/or treatment in older adults
include nephrotoxicity, nausea and vomiting, electrolyte abnorm-
alities, ototoxicity, myelosuppression, and peripheral neuropathy.
Cisplatin can be directly nephrotoxic to the renal tubules;
therefore, it must be used with caution in older adults who may
already have impaired renal function. The dose of cisplatin should
be adjusted if the glomerular filtration rate is 30–50mlmin
 1, and
it should not be given if creatinine clearance is o30mlmin
 1. The
risk of cisplatin-induced nephrotoxicity can be ameliorated with
intravenous hydration, and mannitol or furosemide diuresis.
Carboplatin is not directly toxic to the renal tubules; however,
since the drug is cleared renally, renal impairment will lead to
increased drug levels. The clearance of carboplatin is linearly
related to the patient’s glomerular filtration rate. The Calvert
formula, which takes into account a patient’s glomerular filtration
rate, is used to calculate the dose of carboplatin based on the
desired AUC (Go and Adjei, 1999). A study of platinum-based
chemotherapy for non-small cell lung cancer demonstrated that
older patients were at increased risk for toxicity. In particular,
compared with younger patients, older women were more likely to
lose weight and older men were more likely to experience
neuropsychiatric side effects and leucopenia (Langer et al, 2002).
Oxaliplatin Oxaliplatin is a platinum compound that is increas-
ingly being used for the treatment of colon cancer. The most
common toxicities include myelosuppression, nausea/vomiting,
and neuropathy. A pharmacokinetic study of oxaliplatin in 25
patients between the ages of 26 and 72 demonstrated no
association between oxaliplatin pharmacokinetics and age; how-
ever, the clearance of oxaliplatin was associated with glomerular
filtration rate (Graham et al, 2000). A pharmacokinetic study of
oxaliplatin performed in 37 patients between the ages of 32 and 86,
with varying degrees of renal dysfunction, and demonstrated an
Table 1 Impact of age on the pharmacokinetic (pK) studies of chemotherapy drugs
Author Drug Ages pK analysis (n) Results
Lichtman et al (2006) Paclitaxel 55–86 153 Age-related decrease in clearance
Fidias et al (2001) Paclitaxel 70–85 13 No age-related difference in pK
Smorenburg et al (2003) Paclitaxel 22–84 23 Age-related decrease in clearance
Slaviero et al (2004) Docetaxel 40–83 54 No age-related difference in pK
Hurria et al (2006) Docetaxel 66–84 19 No age-related difference in pK
Minami et al 2004 Docetaxel and cisplatin 39–86 52 No age-related difference in pK
ten Tije et al (2005) Docetaxel 26–80 40 No age-related difference in pK
Graham et al (2000) Oxaliplatin 26–72 25 No age-related difference in pK
Jen et al (2000) Temozolomide 18–82 445 No age-related difference in pK
Sorio et al (1997) Vinorelbine 66–81 10 No age-related difference in pK
Gauvin et al (2000) Vinorelbine 65–79 12 Age-related decrease in clearance
Milano et al (1992) 5-Fluorouracil 25–91 380 No age-related difference in pK
Cassidy et al (1999) Capecitabine 41–80 25 No age-related difference in pK
Toffoli et al (2001) Etoposide 50–83 50 No age-related difference in pK
Miller et al (1997) Etoposide and cisplatin o50–70+
a 106 Age-related decrease in clearance
Ando et alet al (1999) Etoposide 75–84 12 No age-related difference in pK
Li and Gwilt (2003) Doxorubicin 12–74 56 Age-related decrease in Clearance
Dees et al (2000) Doxorubicin and cyclophosphamide
a 24 No age-related difference in pK
aExact age range not specified.
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the clearance of ultra-filterable platinum; however, there was no
significant increase in side effects in patients with mild to
moderate renal dysfunction. Therefore, the authors concluded
that dose reductions were unnecessary in patients with a creatinine
clearance of X20mlmin
 1 (Takimoto et al, 2003). The impact of
severe renal impairment on the clearance of oxaliplatin still
remains unknown. There is no significant alteration in the
clearance of oxaliplatin in patients with liver dysfunction
(Doroshow et al, 2003).
Temozolomide Temozolomide is administered orally, and food
decreases its absorption. The impact of age on the pharmaco-
kinetics of temozolomide was evaluated in a cohort of 445 patients
with a mean age of 50 (range 18–82) who were enrolled in phase I
and II studies. There was no significant association between
patient age and the pharmacokinetics of temozolomide; however,
there was an association of age, female gender, and temozolomide
exposure with myelosuppression. The most important factor
influencing the clearance of temozolomide was body surface area:
increased body surface area was associated with increased
clearance (Jen et al, 2000).
Vinca alkaloids
Vinorelbine The vinca alkaloid, vinorelbine, is primarily excreted
through the biliary tract. Dose adjustment in patients with severe
biliary disease has been recommended. Two studies of small
sample size evaluated the impact of age on the pharmacokinetics of
vinorelbine, and yielded conflicting results. Sorio et al (1997)
studied the pharmacokinetics of vinorelbine in 10 patients age
X65 and found no age-related change in pharmacokinetics or
toxicity. In contrast, Gauvin et al (2000) evaluated the pharmaco-
kinetics of vinorelbine in 12 patients age X65 and found a
significant age-related decrease in vinorelbine clearance, estimated
as a 30–40% clearance decrease for patients age X70. An increase
in the AUC of vinorelbine was associated with an increased risk of
haematologic toxicity (Gauvin et al, 2000). Further studies
regarding the impact of age on the pharmacokinetics and
pharmacodynamics of vinorelbine are needed.
Antimetabolites
5-fluorouracil The antimetabolite, 5-fluorouracil (5FU), is meta-
bolised hepatically. Its pharmacokinetics was evaluated in a cohort
of 380 patients ages 25–91, but no significant impact of age was
found. However, there were differences in 5FU clearance by
gender. In particular, women had a significantly lower clearance of
5FU because of lower dihydropyrimidine dehydrogenase activity,
the key enzyme involved in the clearance of 5FU (Milano et al,
1992). Other studies have demonstrated that older patients
receiving 5FU are at increased risk for leucopenia and mucositis
(Popescu et al, 1999; Sargent et al, 2001).
Capecitabine The oral fluoropyrimidine, capecitabine, is absorbed
in the gastrointestinal tract, then enzymatically converted to 5FU
in the liver. Caution must be used in patients with liver
dysfunction, as there are no clear dosing guidelines for capecita-
bine in patients with severe hepatic impairment. Capecitabine and
its metabolites are primarily excreted in the urine, and a
pharmacokinetics study of capecitabine in patients with varying
degrees of renal dysfunction demonstrated that they have
increased systemic exposure to capecitabine and an increased risk
of grade 3 or 4 toxicity (Poole et al, 2002). The dose of capecitabine
needs to be adjusted if a patient’s creatinine clearance is
o50mlmin
 1, and capecitabine should not be prescribed in
patients with a creatinine clearance o30mlmin
 1.
There is a potential for drug interactions with capecitabine.
Concomitant exposure to capecitabine and warfarin leads to
exaggerated anticoagulant activity (Camidge et al, 2005). Thus, the
international normalised ratio needs to be monitored carefully
when prescribing capecitabine to a patient who takes warfarin. In
addition, there is a potential for interaction between folate
supplementation and capecitabine. In a study of patients with
colorectal cancer receiving capecitabine, those with higher
pretreatment levels of serum folate experienced greater toxicity
during cycle 1 and over the treatment period (Sharma et al, 2006).
Methotrexate Methotrexate, a component of the CMF (cyclo-
phosphamide, methotrexate, 5FU) regimen for treatment of breast
cancer, is associated with an increased risk of toxicity in older
adults. This antifolate is eliminated renally and the clearance of
methotrexate decreases with decreased creatinine clearance;
therefore, the dosing of methotrexate should be adjusted based
on renal function (Bressolle et al, 1998). In a study by Gelman and
Taylor (1984), the age-related increase in toxicity with CMF was
eliminated by modifying the doses of methotrexate and cyclopho-
sphamide based on renal function, and empirically decreasing the
dose of 5FU by two-thirds. However, it is not known if this
approach affects the efficacy of the therapy (Gelman and Taylor,
1984). Caution is required in prescribing methotrexate for patients
with metastatic cancer who have ascites or pleural effusion, which
can lead to prolonged elimination of methotrexate and increased
toxicity.
Cytosine arabinoside Cytosine arabinoside (ara-C) is rapidly
eliminated from plasma by deamination. Approximately 70–80%
of a given dose is excreted as ara-U. Older adults are at increased
risk for toxicity with high-dose ara-C because of age-related
alterations in renal function. In particular, risk factors for ara-C-
associated neurotoxicity include a creatinine X1.2mgdl
 1, age
X40, and alkaline phosphatase X3 times normal (Rubin et al,
1992). The incidence of neurotoxicity can be reduced if dosing
takes renal function into account (Smith et al, 1997).
Topoisomerase inhibitors
Etoposide Etoposide is a topoisomerase II inhibitor. The
clearance of etoposide is slower in patients with impaired renal
function (Toffoli et al, 2001). In contrast, there is no significant
difference in the pharmacokinetics of etoposide in patients with
impaired hepatic function (Aita et al, 1999; Toffoli et al, 2001).
Studies evaluating the impact of age on the pharmacokinetics of
etoposide have produced conflicting results. Toffoli et al (2001)
studied 50 patients ranging in age from 50 to 83. They found no
impact of age on the pharmacokinetics of etoposide when taking
creatinine clearance into account. Miller et al (1997) evaluated 106
patients who received etoposide in combination with cisplatin, and
reported that older age was associated with an increase in free and
trough etoposide concentrations. Ando et al (1999) evaluated the
pharmacokinetics of oral etoposide in 12 patients ranging from age
75 to 84, and detected no difference in the etoposide pharmaco-
kinetics of this group in comparison with historical data from
younger patients. However, they did find that older patients were
at increased risk for myelosuppressive complications.
Anthracyclines
Doxorubicin Doxorubicin is primarily metabolised hepatically. Li
and Gwilt (2003) evaluated the impact of age on the pharmaco-
kinetics of doxorubicin in 56 patients between the ages of 12 and
74. Increased age was associated with decreased clearance of
doxorubicin. Dees et al (2000) evaluated the pharmacokinetics of
AC (doxorubicin 60mgm
 2 and cyclophosphamide 600mgm
 2)
in 24 patients. There was no impact of age on the clearance of
Clinical pharmacology of cancer therapies
A Hurria and SM Lichtman
519
British Journal of Cancer (2008) 98(3), 517–522 & 2008 Cancer Research UKdoxorubicin or cyclophosphamide; however, older adults were at
increased risk for myelosuppression. Age is a known risk factor for
congestive heart failure in older adults who receive doxorubicin.
Swain et al (2003) evaluated a cohort of 630 patients who received
doxorubicin vs placebo in three phase III clinical trials, and found
an association between older age and the risk of congestive heart
failure after a cumulative doxorubicin dose of 400mgm
 2.
FURTHER RESEARCH
There are limited data available regarding the impact of age on the
pharmacokinetics and pharmacodynamics of targeted therapies.
This area needs much more research. Some data do suggest an
association between age and risk of toxicity with targeted
therapies. For example, increasing age is a risk factor for
congestive heart failure associated with trastuzumab, the huma-
nised monoclonal antibody that targets the HER-2 (human
epidermal growth factor receptor 2) protein. This was demon-
strated in the NSABP B31 study of doxorubicin and cyclo-
phosphamide followed by paclitaxel with or without trastuzumab
for the adjuvant treatment of patients with HER-2/neu-positive
breast cancer. In this study, risk factors for trastuzumab-associated
congestive heart failure included older age (defined as age X50)
and a lower left ventricular ejection (defined as post-AC ejection
fraction of 50–54%). There was a 20% (95% CI, 11.1–35.9), 3-year
cumulative incidence of congestive heart failure in patients age
X50 who received adjuvant trastuzumab with a left ventricular
ejection fraction of 50–54% after AC (Tan-Chiu et al, 2005). It is
unclear whether this was solely a pharmacodynamic effect of
trastuzumab on cardiac function or whether an age-related change
in trastuzumab pharmacokinetics may also have played a role.
Another example of age-related toxicity with targeted therapy is
seen among patients receiving bevacizumab, the humanised
monoclonal antibody that inhibits vascular endothelial growth
factor (VEGF). A retrospective pooled analysis of five randomised
studies in 1745 patients demonstrated that patients age X65, who
were treated with chemotherapy and bevacizumab, had an
increased risk of arterial thromboembolic events compared with
those age o65 (7.1 vs 2.5%). Risk factors for development of an
arterial thromboembolic event included age 465 (P¼0.01) and
history of a prior arterial thromboembolic event (Po0.001)
(Scappaticci et al, 2007).
A phase III study (E3200) in patients with metastatic colon
cancer receiving bevacizumab and 5FU, leucovorin, and oxaliplatin
demonstrated that patients age X65 had an increased risk of
gastrointestinal side effects and fatigue compared with younger
individuals. In addition, in a phase III study (E4599) of patients
with advanced non-small cell lung cancer who received paclitaxel
and carboplatin, and who were randomised to receive or not to
receive bevacizumab, demonstrated that older adults were at
increased risk for developing proteinuria.
There are limited data regarding the age-related pharmacoki-
netics or pharmacodynamics of other commonly used targeted
agents, such as erlotinib, cetuximab, and sunitinib. A phase II
study of erlotinib as first line therapy for patients age 70 and older
with advanced non-small cell lung cancer demonstrated that 12%
of patients on the study required discontinuation of therapy, most
commonly due to interstitial lung disease, dehydration, and
diarrhoea. There was one treatment related death attributed to
interstitial lung disease. This trial did not include a direct
comparison of older and younger adults; however, the rate of
treatment discontinuation reported in this trial was higher than the
rate of treatment discontinuation reported in previous clinical
trials of patients with a younger mean age (Jackman et al, 2007).
The mechanism behind this age-related increase in side effects
with targeted therapies is unclear, and studies are needed to
address these questions.
CONCLUSIONS
Despite the aging of the population and the association of cancer
with aging, the pharmacokinetics and pharmacodynamics of
anticancer therapies have been understudied in older adults. Most
of the studies performed to date have not demonstrated significant
age-related differences in the pharmacokinetics of cancer thera-
pies; however, the majority of the studies consisted of small sample
size and would not be able to detect a subtle change. In addition,
chronologic age is only one factor to consider. Other measures of
physiological age that may affect tolerance to cancer therapy in
older adults should also be captured, including functional status,
other comorbid medical conditions, concomitant medications,
nutritional status, and renal and hepatic function. As new drugs
are introduced into oncology treatment, phase II studies of the
pharmacokinetics and pharmacodynamics of cancer therapies in
older adults, which captures all of these factors, are needed in
order to determine the optimum treatment for this growing
population of older patients with cancer.
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